Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SCARLET FEVER”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2002

Hepatitis and hematuria in scarlet fever.

Scarlet fever is a common and usually benign course when treated properly. Hepatitis due to scarlet fever has been described mostly in adults. A 2 1/2-year-old boy presented with scarlet fever and jaundice, hematuria and elevated liver enzymes.

Child, Preschool↗
PubMed2000

Reactivity of rheumatic fever and scarlet fever patients' sera with group A streptococcal M protein, cardiac myosin, and cardiac tropomyosin: a retrospective study.

Archived sera (collected in 1946) from acute rheumatic fever (ARF) and untreated scarlet fever and/or pharyngitis patients were reacted with streptococcal M protein, cardiac myosin, and cardiac tropomyosin. Except for very low levels to tropomyosin, antibodies to other antigens were not elevated in the sera of ARF patients relative to those of non-ARF patients, even though there was roughly equivalent exposure to group A streptococci. This suggests that antibodies to these molecules may not play a central role in the induction of ARF.

Acute Disease↗
PubMed1987

Anti-streptopolysaccharide antibody in children with rheumatic fever and scarlet fever.

As the serological test of streptococcal infection, the measurement of anti-exotoxin antibodies such as ASO is widely practiced. M protein of the cell wall of group A streptococcus has type specificity. To detect the anti M protein antibody is very significant, but it is not easy to apply this to clinical practice because there are many types and because of the difficulty of purifying M protein. C polypeptide has group specificity, so the measurement of the antibody to C polypeptide is very important as the serological test of group A streptococcus.

Antibodies, Bacterial↗
PubMedDate not supplied

Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever.

This review of the medical literature reveals that the incidence of rheumatic fever has been declining for at least 150 years, preceding by many decades the use of penicillin as a preventive measure. Simultaneously, the prevalence of rheumatic heart disease has diminished. Streptococcal upper respiratory tract infections remain common but with reduced severity and fewer subsequent cases of rheumatic fever. Scarlet fever has become relatively benign, with low mortality. Whether recent sporadic outbreaks of rheumatic fever due to known rheumatogenic strains of group A streptococci will have a significant effect on morbidity and mortality trends remains to be seen. Relatively high rates of rheumatic fever and rheumatic heart disease in developing countries are difficult to evaluate because of irregularities in reporting and investigative procedures.

Humans↗
PubMedDate not supplied

[Antibiotic prophylaxis of immediate and late complications of scarlet fever].

Patients with scarlet fever were followed by clinical and laboratory investigation (bacteriologic and immunologic reactions, etc.), in relation with the early application, and the duration of penicillin therapy. The patients were also followed for a period of 30 days after discharge from the hospital. The results show a decrease in the number of early and late complications, as well as a reduction in the number of carriers of beta-haemolytic streptococcus in those patients in whom penicillin treatment was applied early, and when it was prolonged in the recovery period. The clinical and statistical data stress the pathologic morphology of scarlet fever, and the restructuration of complications when penicillin treatment is applied.

Glomerulonephritis↗